High-resolution photon-counting CT images enable improved visualization and quantitative assessment of coronary plaques and stents as assessed in a phantom model. Purpose To compare the performance of energy-integrating detector (EID) CT, photon-counting detector CT (PCCT), and high-resolution PCCT (HR-PCCT) for the visualization of coronary plaques and redu...
6 January 2021 in CardioVascular and Interventional Radiology
Purpose: To evaluate lyso-thermosensitive liposomal doxorubicin (LTLD, ThermoDox®) in combination with loco-regional mild hyperthermia (HT) for targeted drug delivery to the bladder wall and potential treatment of bladder cancer. Material and methods: Porcine in vivo studies were performed with the following groups: (i) intravenous (IV) LTLD with hyperthermia (LTLD + HT); (ii) IV doxorubicin (DOX) with hyperthermia (IV DOX + HT) and (iii) IV LTLD without hyperthermia (LTLD – HT). Drug formulations were delivered via 30 min IV infusion coinciding with 1-h bladder irrigation (45 °C water for HT groups, 37 °C for non-HT group), followed by immediate bladder resection. DOX concentrations were measured in consecutive sections parallel to the bladder lumen by liquid chromatography following drug extraction. Computer models were developed to simulate tissue heating and drug release from LTLD. Results: Comparing mean DOX concentrations at increasing depths from the lumen to outer surface of the bladder wall, the ranges for LTLD + HT, IV DOX + HT and LTLD – HT, respectively, were 20.32–3.52 μg/g, 2.34–0.61 μg/g and 2.18–0.51 μg/g. The average DOX concentrations in the urothelium/lamina and muscularis, respectively, were 9.7 ± 0.67 and 4.09 ± 0.81 μg/g for IV LTLD + HT, 1.2 ± 0.39 and 0.86 ± 0.24 μg/g for IV DOX + HT, and 1.15 ± 0.38 and 0.62 ± 0.15 μg/g for LTLD – HT. Computational model results were similar to measured DOX levels and suggest adequate temperatures were reached within the bladder wall for drug release from LTLD. Conclusions: Doxorubicin accumulation and distribution within the bladder wall was achieved at concentrations higher than with free IV doxorubicin by mild bladder hyperthermia combined with systemic delivery of LTLD.
The immune response to radiofrequency ablation (RFA) and cryoablation (CRA) was characterized and compared in a colon cancer mouse model. All studies were conducted under a research protocol approved by the National Institutes of Health, Clinical Center, Animal Care and Use Committee. BALB/cJ mice were inoculated with CT26 cells, and randomized to RFA, CRA, or sham treatment. Mice were sacrificed 3 days post-treatment, and tumor, spleen, and serum were harvested. Cell death was determined by Caspase-3 immunohistochemical and TUNEL stains. Immune response was analyzed using flow cytometry, serum cytokine assay and immunohistochemistry. Cell death, necrosis, and apoptosis induced by ablation were comparable in RFA and CRA. Decreased frequency of systemic T-regulatory cells was found in the CRA group. Both RFA and CRA reduced frequencies of several myeloid-derived suppressor cell (MDSC) subpopulations. RFA induced pro-inflammatory cytokine secretion including TNF-α and IL-12 as well as anti-inflammatory cytokines IL-5, and IL-10. CRA augmented secretion of a wider array of cytokines compared to RFA with both pro- and anti-inflammatory properties including IL-1β, IL-5, IL-6, IL-10, and KC GRO. In the tumor microenvironment, RFA reduced the number of T-regulatory cells, a finding not observed with CRA. Reduction of immune suppression via decreases in T-regulatory cells and MDSC was found to be induced by RFA or CRA. CRA augmented a wider range of cytokines than RFA, which were mainly pro-inflammatory, but also anti-inflammatory. In the tumor microenvironment, RFA demonstrated more pronounced anti-tumoral immunity. Further delineation of specific immunomodulation induced by ablation could inform drug-device development and may play a role in future hypothesis-driven immunomodulatory paradigms that combine immunotherapy drugs with tumor destruction for the treatment of metastatic colon cancer.
27 August 2020 in IEEE Transactions on Radiation and Plasma Medical Sciences
Photon-counting CT (PCCT) detectors are the next step in advancing CT system development and will replace the current energy-integrating detectors (EIDs) in CT systems in the near future. In this context, the performance of PCCT was compared to EID CT for three clinically relevant tasks: 1) abdominal soft tissue imaging, where differentiating low contrast features is important; 2) vascular imaging, where iodine detectability is critical; and 3) high-resolution skeletal and lung imaging. A multitiered phantom was imaged on an investigational clinical PCCT system (Siemens Healthineers) across different doses using three imaging modes: macro and ultrahigh resolution (UHR) PCCT modes and EID CT. Images were reconstructed using filtered backprojection and soft tissue (B30f), vascular (B46f), or high-resolution (B70f; U70f for UHR) kernels. Noise power spectra, task transfer functions, and detectability index were evaluated. For a soft tissue task, PCCT modes showed comparable noise and resolution with improved contrast-to-noise ratio. For a vascular task, PCCT modes showed lower noise and improved iodine detectability. For a high resolution task, macro mode showed lower noise and comparable resolution while UHR mode showed higher noise but improved spatial resolution for both air and bone. PCCT offers competitive advantages to EID CT for clinical tasks.
1 May 2020 in Journal of Vascular and Interventional Radiology